Straits Times Index
3,303.19 +10.26 (+0.31%) S&P 500
5,127.79 +63.59 (+1.26%) Dow
38,675.68 +449.98 (+1.18%) Nasdaq
16,156.33 +315.33 (+1.99%) Bitcoin USD
63,583.34 -161.64 (-0.25%) CMC Crypto 200
1,375.64 +63.02 (+4.80%)
Intra-Cellular Therapies, Inc. (ITCI)
Pre-market:
- Zacks
Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Tuesday, May 7, 2024, to provide a corporate update and discuss details of the Company's financial results for the quarter ended March 31, 2024. To attend the live con
- Zacks
Will Intra-Cellular Therapies (ITCI) Report Negative Q1 Earnings? What You Should Know
Intra-Cellular (ITCI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
